ABBVIE INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
ABBVIE INC. - More news...
ABBVIE INC. - More news...
- AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis
- AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer
- AbbVie to Host Second-Quarter 2024 Earnings Conference Call
- Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
- AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
- AbbVie Acquires Celsius Therapeutics
- Introducing Allē Payment Plans, Powered by Cherry
- U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
- AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
- AbbVie Declares Quarterly Dividend
- AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
- U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
- AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
- AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
- AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
- SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
- AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
- AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
- RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
- Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50
- AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
- AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
- AbbVie Completes Acquisition of Landos Biopharma
- BaseLaunch announces a new partnership with AbbVie
- AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
- AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
- AbbVie to Present at the Bank of America Securities Healthcare Conference
- AbbVie Reports First-Quarter 2024 Financial Results
- New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
